Dihydrotanshinone I Inhibits Pancreatic Cancer Progression via Hedgehog/Gli Signal Pathway

doi:10.2174/1568009623666230328123915

科研成果详情

题名	Dihydrotanshinone I Inhibits Pancreatic Cancer Progression via Hedgehog/Gli Signal Pathway
作者	Huang, Wenqian 1; Dai, Yile1; Xu, Liming 1; Mao, Yefan1; Huang, Zhengwei 1; Ji, Xiaoke 2
发表日期	2023
发表期刊	Current cancer drug targets 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Dihydrotanshinone ? Hedgehog/Gli signal pathway Pancreatic Cancer apoptosis epithelial-mesenchymal transformation proliferation
其他关键词	15,16-DIHYDROTANSHINONE I ; KAPPA-B ; ACTIVATION ; STATISTICS ; APOPTOSIS ; INVASION ; TWIST ; EMT
摘要	Pancreatic cancer is highly fatal and its incidence is rising worldwide. Its poor prognosis is attributed to a lack of effective diagnostic and therapeutic strategies. Dihydrotanshinone Ⅰ (DHT), a phenanthrene quinone liposoluble compound from Salvia miltiorrhiza Bunge (Danshen), exerts anti-tumor effects by inhibiting cell proliferation, enhancing apoptosis, and inducing cell differentiation. However, its effects on pancreatic cancer are unclear., The role of DHT in the growth of tumor cells was explored using real-time cell analysis (RTCA), colony formation assay, and CCK-8. The effects of DHT on tumor cells invasion as well as migration were assessed by Transwell and migration assays. Expressions of pro-apoptosis and metastasis factors in tumor cells were examined using western blot. Tumor apoptosis rates were studied using flow cytometry. The anticancer effect of DHT in vivo was assessed by tumor transplantation into nude mice., Our analyses show that DHT has a suppressive role in epithelial-mesenchymal transition (EMT), invasiveness, proliferation, as well as migratory ability of Patu8988 and PANC-1 cells via Hedgehog/Gli signaling. Moreover, it drives apoptosis via caspases/BCL2/BAX signaling. Experiments in nude mice transplanted with tumors have shown DHT to have anticancer effects in vivo., Our data show that DHT effectively suppresses pancreatic cancer cell proliferation as well as metastasis, and induces apoptosis via Hedgehog/Gli signaling. These effects have been reported to be dose- and time-dependent. Therefore, DHT can be exploited as a potential treatment for pancreatic cancer.
出版者	BENTHAM SCIENCE PUBL LTD
ISSN	1568-0096
EISSN	1873-5576
卷号	23 期号:9 页码:731-741
DOI	10.2174/1568009623666230328123915
页数	11
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:001031597700005
收录类别	PUBMED ; SCIE ; SCOPUS
URL	查看原文
PubMed ID	37018533
SCOPUSEID	2-s2.0-85164237425
通讯作者地址	[Huang, Zhengwei]Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province,Zhejiang Provincial Top Key Discipline in Surgery,First Affiliated Hospital of Wenzhou Medical University,Zhejiang Province,Wenzhou,China ; [Ji, Xiaoke]Department of Hepatobiliary Surgery,First Affiliated Hospital of Wenzhou Medical University,Zhejiang Province,Wenzhou,China
Scopus学科分类	Oncology;Pharmacology;Drug Discovery;Cancer Research
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/174257
专题	附属第一医院_肝胆外科
通讯作者	Huang, Zhengwei; Ji, Xiaoke
作者单位	1.Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province,Zhejiang Provincial Top Key Discipline in Surgery,First Affiliated Hospital of Wenzhou Medical University,Zhejiang Province,Wenzhou,China; 2.Department of Hepatobiliary Surgery,First Affiliated Hospital of Wenzhou Medical University,Zhejiang Province,Wenzhou,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Huang, Wenqian,Dai, Yile,Xu, Liming,et al. Dihydrotanshinone I Inhibits Pancreatic Cancer Progression via Hedgehog/Gli Signal Pathway[J]. Current cancer drug targets,2023,23(9):731-741.
APA	Huang, Wenqian, Dai, Yile, Xu, Liming, Mao, Yefan, Huang, Zhengwei, & Ji, Xiaoke. (2023). Dihydrotanshinone I Inhibits Pancreatic Cancer Progression via Hedgehog/Gli Signal Pathway. Current cancer drug targets, 23(9), 731-741.
MLA	Huang, Wenqian,et al."Dihydrotanshinone I Inhibits Pancreatic Cancer Progression via Hedgehog/Gli Signal Pathway".Current cancer drug targets 23.9(2023):731-741.